Eric Q. Wu
Beijing, Boston, Brussels, London, Paris
Education
Ph.D., pharmacoeconomics and policy, M.S., health care regulation and law, and M.A., economics, University of Southern California; B.S., Peking University
Summary of Experience
Dr. Wu is a health economist with expertise in health economics and outcomes research (HEOR), market access, and scientific evidence strategy. He has conducted research in more than 30 countries on behalf of pharmaceutical and medical device companies, payers, providers, and government agencies. Dr. Wu has contributed to over 200 publications across dozens of therapeutic areas, including regenerative therapies (gene and stem cell), rare and ultra-rare diseases, biologics, and immuno-oncology.
Dr. Wu spends a significant portion of his practice developing new scientific methods to address challenges in health care research. He has developed client-focused solutions based on the use of artificial intelligence (AI), medical big data, real-world evidence, and innovative comparative-effectiveness research methodologies.
Selected Cases
Selected Publishing
-
Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study
Dermatology and Therapy, August 8, 2023
2023Kimball AB, Delevry D, Yang M, Chuang C, Wang Z, Bégo-Le-Bagousse G, Martins B, Wu EQ, Shumel B, Wang J, Sierka D, Chao J, Strober B
-
Treatment Patterns and Healthcare Resource Use in Medicare Beneficiaries with Parkinson's Disease
ClinicoEconomics and Outcomes Research, 2023
2023 -
Treatment Patterns and Adverse Event-Related Hospitalization Among Patients with Epidermal Growth Factor Receptor (EGFR)-Mutated Metastatic Non-small Cell Lung Cancer After Treatment with EGFR Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy Regimens
Drugs – Real World Outcomes, 2023
2023Marrett E, Kwong WJ, Xie J, Manceur AM, Sendhil SR, Wu E, Ionescu-Ittu R, Subramanian J
-
Real-world Data for Healthcare Research in China: Call for Actions
Value in Health Regional Issues, Volume 27, 2022
2022 -
-
Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States
Journal of Managed Care & Specialty Pharmacy, 2022
2022Kim N, Wang J, Burudpakdee C, Song Y, Ramasamy A, Xie Y, Sun R, Kumar N, Wu EQ, Sullivan SD
-
-
The Economic Burden of Eosinophilic Gastritis and Eosinophilic Enteritis in the United States
Advances in Therapy, 2022
2022Woolley M, Cook EE, Mu F, Betts KA, Billmyer E, Yim E, Chen J, Wu EQ
-
Health-care resource use and costs associated with diabetic and idiopathic gastroparesis: A claims analysis of the first 3 years following the diagnosis of gastroparesis
Neurogastroenterology & Motility, 2022
2022Chen YJ, Tang W, Ionescu-Ittu R, Ayyagari R, Wu E, Huh SY, Parkman HP
-
Chronic Myeloid Leukemia: Part I-Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States
Journal of Health Economics and Outcomes Research, 2022
2022Atallah EL, Maegawa R, Latremouille-Viau D, Rossi C, Guérin A, Wu EQ, Patwardhan P
-
Real-World Management of Hyperkalemia in the Emergency Department: An Electronic Medical Record Analysis
Advances in Therapy, 2022
2022Davis J, Israni R, Betts KA, Mu F, Cook EE, Anzalone D, Szerlip H, Yin L, Uwaifo GI, Wu EQ
-
Surgical Treatment Patterns, Healthcare Resource Utilization, and Economic Burden in Patients with Tenosynovial Giant Cell Tumor Who Underwent Joint Surgery in the United States
Journal of Health Economics and Outcomes Research, 2022
2022 -
Healthcare resource utilization and costs in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis
Journal of Medical Economics, 2021
2021Stein EM, Bonifacio G, Latrémouille-Viau D, Shi S, Guérin A, Wu EQ, Sadek I, Cao X
-
Inpatient Management and Post-Discharge Outcomes of Hyperkalemia
Hospital Practice, 2021
2021Davis J, Israni R, Mu F, Cook E, Szerlip H, Uwaifo G, Fonseca V, Betts K
-
Health care resource utilization and cost burden of hemophilia B in the United States
Blood Advances, 2021
2021Buckner TW, Bocharova I, Hagan K, Bensimon AG, Yang H, Wu EQ, Sawyer EK, Li N
-
The impact of achieving and maintaining near-complete or complete skin clearance on patient quality of life in moderate-to-severe psoriasis
Journal of the American Academy of Dermatology, 2021
2021Ryan C, Puig L, Zema C, Thompson E, Yang M, Wu EQ, Bensimon A, Huang X, Joshi AD, Elewski B
-
The Risk Reduction of Accidental Exposure-Related Systemic Allergic Reactions Extrapolated Based on Food Challenge Data After 1 Year of Peanut Oral Immunotherapy
Advances in Therapy, 2021
2021Yu S, Smith A, Hass S, Wu E, Chai X, Zhou J, Ayyagari R, Liu JS, Robison D, Donelson SM, Tilles S
-
Real-world migraine-related healthcare resource utilization and costs associated with improved vs. worsened/stable migraine: a panel-based chart review in France, Germany, Italy, and Spain
Journal of Medical Economics, 2021
2021Vo P, Swallow E, Wu E, Zichlin ML, Katcher N, Maier-Peuschel M, Naclerio M, Ritrovato D, Joshi TSP, Ferraris M
-
Determinants of Hyperkalemia Progression Among Patients with Mild Hyperkalemia
Advances in Therapy, 2021
2021Israni R, Betts KA, Mu F, Davis J, Wang J, Anzalone D, Uwaifo GI, Szerlip H, Fonseca V, Wu E
-
Hemophilia Gene Therapy Value Assessment: Methodological Challenges and Recommendations
Value in Health, 2021
2021Garrison LP, Pezalla E, Towse A, Yang H, Faust E, Wu EQ, Li N, Sawyer EK, Recht M
-
Prevalence of Metabolic Acidosis Among Patients with Chronic Kidney Disease and Hyperkalemia
Advances in Therapy, 2021
2021Cook EE, Davis J, Israni R, Mu F, Betts KA, Anzalone D, Yin L, Szerlip H, Uwaifo GI, Fonseca V, Wu EQ
-
Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia in Japan
Transplantation and Cellular Therapy, 2021
2021Wakase S, Teshima T, Zhang J, Ma Q, Watanabe Y, Yang H, Qi CZ, Chai X, Xie Y, Wu EQ, Igarashi A
-
Cost Effectiveness Analysis of Tisagenlecleucel for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma in Japan
Transplantation and Cellular Therapy, 2021
2021Wakase S, Teshima T, Zhang J, Ma Q, Fujita T, Yang H, Chai X, Qi CZ, Liu Q, Wu EQ, Igarashi A
-
Treatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis
Leukemia & Lymphoma, 2021
2021Stein EM, Bonifacio G, Latremouille-Viau D, Shi S, Guerin A, Wu EQ, Sadek I, Cao X
-
The Economic Burden of Tenosynovial Giant Cell Tumors Among Employed Workforce in the United States
Journal of Occupational and Environmental Medicine, 2021
2021Lin F, Ionescu-Ittu R, Pivneva I, Wynant W, Shi S, Wu EQ, Kwong WJ, Abraham JA
-
The Development of Health Technology Assessment in Asia: Current Status and Future Trends
Value in Health Regional Issues, Volume 21, May 2020
2020 -
A Review of Two Regulatory Approved Anti-CD19 CAR T-Cell Therapies in Diffuse Large B-Cell Lymphoma: Why Are Indirect Treatment Comparisons Not Feasible?
Advances in Therapy, 2020
2020Zhang J, Li J, Ma Q, Yang H, Signorovitch J, Wu E
-
Estimation of Total Costs in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Receiving Tisagenlecleucel from a U.S. Hospital's Perspective
Journal of Managed Care & Specialty Pharmacy, 2020
2020 -
Estimation of total costs in patients with relapsed or refractory diffuse large B-cell lymphoma receiving tisagenlecleucel from a US hospital’s perspective
Journal of Medical Economics, 2020
2020 -
Prevalence and economic burden of hyperkalemia in the United States Medicare population
Current Medical Research and Opinion
2020 -
Postdischarge Health Care Costs and Readmission in Patients With Hyperkalemia-Related Hospitalizations
Kidney International Reports, 2020
2020 -
Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials
JAMA Dermatology, 2020
2020Augustin M, Lambert J, Zema C, Thompson EHZ, Yang M, Wu EQ, Garcia-Horton V, Geng Z, Valdes JM, Joshi A, Gordon KB
-
An overview of patients with haemophilia A in China: Epidemiology, disease severity and treatment strategies
Haemophilia, 27 November 2020
2020Song X, Zhong J, Xue F, Chen L, Li H, Yuan D, Xie J, Shi J, Zhang L, Wu E, Yang R
-
Real‐world analysis of haemophilia patients in China: A single centre’s experience
Haemophilia, 20 May 2020
2020Song X, Liu W, Xue F, Zhong J, Yang Y, Liu Y, Xie, J, Wu E, Zhang L, Shi J, Yang R
-
The cost-effectiveness of low-dose budesonide as a Step 2 treatment for pediatric asthma in China
Journal of Comparative Effectiveness Research, 2020
2020Wang X, Fang H, Shen K, Liu T, Xie J, Liu Y, Zhong J, Wu E, Zhou W, Wu B
-
Cost-effectiveness analysis of double low-dose budesonide and low-dose budesonide plus montelukast among pediatric patients with persistent asthma receiving Step 3 treatment in China
Journal of Medical Economics, 2020
2020Wang X, Fang H, Shen K, Liu T, Xie J, Liu Y, Wu P, Chen Y, Zhong J, Wu E, Zhou W, Wu B
-
Clinical and Economic Outcomes of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Post-Bundling Era
Kidney Medicine, 2020
2020Cizman B, Smith HT, Camejo RR, Casillas L, Dhillon H, Mu F, Wu E, Xie J, Zuckerman P, Coyne D
-
Transparency in Health Economic Modeling: Options, Issues and Potential Solutions
PharmacoEconomics, 2019
2019 -
Assessing Patient Preferences for Treatment Decisions for New Direct Acting Antiviral (DAA) Therapies for Chronic Hepatitis C Virus Infections
Advances in Therapy, 2019
2019Welzel TM, Yang M, Sajeev G, Chen YJ, Pinsky B, Bao Y, Wu EQ, Dieterich D
-
Comparative Effectiveness of Non-cisplatin First-line Therapies for Metastatic Urothelial Carcinoma: Phase 2 IMvigor210 Study Versus US Patients Treated in the Veterans Health Administration
European Urology Oncology, 2019
2019Vander Velde N, Guerin A, Ionescu-Ittu R, Shi S, Wu EQ, Lin SW, Hsu LI, Saum KU, de Ducla S, Wang J, Li S, Thåström A, Liu S, Shi L, Leppert JT
-
Economic Impact of Non-Medical Switching from Originator Biologics to Biosimilars: A Systematic Literature Review
Advances in Therapy, 2019
2019 -
The Economic Burden of Nocturia on the U.S. Health Care System and Society: A National Health and Nutrition Examination Survey Analysis
Journal of Managed Care & Specialty Pharmacy, 2019
2019Jhaveri J, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Wu EQ
-
Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1
Advances in Therapy, 2019
2019Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, Pivneva I, Wu EQ, Arjunji R, Feltner D, Sproule DM
-
Assessment of the real-world safety profile of vedolizumab using the United States Food and Drug Administration adverse event reporting system
PLOS One, 2019
2019Cross RK, Chiorean M, Vekeman F, Xiao Y, Wu E, Chao J, Wang AW
-
The prevalence of hyperkalemia in the United States
Current Medical Research and Opinion. 2018 Jun;34(6):971-978
2018 -
Current Treatment Patterns Among Postmenopausal Women with HR+/HER2- Metastatic Breast Cancer in US Community Oncology Practices: An Observational Study
Advances in Therapy. 26 Mar 2018:1-12
2018Goldschmidt D, Dalal AA, Romdhani H, Kelkar S, Guerin A, Gauthier G, Wu EQ, Niravath P, Small T
-
Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis
Current Medical Research and Opinion. Apr 23 2018:1-9
2018Armstrong AW, Betts KA, Signorovitch JE, Sundaram M, Li J, Ganguli AX, Wu EQ
-
-
Number needed to treat and costs per responder among biologic treatments for moderate to severe psoriasis
Current Medical Research and Opinion. 2018 Jul;34(7):1325-1333
2018Armstrong AW, Betts KA, Signorovitch JE, Sundaram M, Li J, Wu EQ
-
Clinical Trajectories, Healthcare Resource Use, and Costs of Diabetic Nephropathy Among Patients with Type 2 Diabetes: A Latent Class Analysis
Diabetes Therapy. Mar 29 2018.
2018 -
Monitoring of Hematologic, Cardiac, and Hepatic Function in Post-Menopausal Women with HR+/HER2- Metastatic Breast Cancer
Advances in Therapy. 2018 Aug;35(8):1251-1264
2018Guérin A, Goldschmidt D, Small T, Gagnon-Sanschagrin P, Romdhani H, Gauthier G, Kelkar S, Wu EQ, Niravath P, Dalal AA
-
A retrospective study evaluating the tolerability and effectiveness of adjunctive antihypertensive drugs in patients with inadequate response to initial treatment
The Journal of Clinical Hypertension. 2018 Jun;20(6):1058-1066
2018Ayyagari R, Xie J, Cheng D, Wu EQ, Huang XY, Chen S
-
Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis
Advances in Therapy; 2017 Jan;34(1):207-220. doi: 10.1007/s12325-016-0443-1. Epub 2016 Dec 2.
2017Harrington R, Lee E, Yang H, Wei J, Messali A, Azie N, Wu EQ, Spalding J.
-
Real-World Outcomes of Acute Ischemic Stroke Treatment with Intravenous Recombinant Tissue Plasminogen Activator
Journal of Stroke and Cerebrovascular Diseases. Sep 2017;26(9):1996-2003
2017Betts KA, Hurley D, Song J, Sajeev G, Guo J, Du EX, Paschoalin M, Wu EQ
-
Readmission Risk in Chronic Obstructive Pulmonary Disease Patients: Comparative Study of Nebulized beta2-Agonists
Drugs Real World Outcomes. Mar 2017;4(1):33-41
2017 -
The economic burden of bipolar I disorder in the United States in 2015
Journal of Affective Disorders. Jan 15 2018;226:45-51
2017Cloutier M, Greene M, Guerin A, Touya M, Wu E
-
Poor early response to methotrexate portends inadequate long-term outcomes in patients with moderate-to-severe psoriasis: Evidence from 2 phase 3 clinical trials
Journal of the American Academy of Dermatology. Dec 2017;77(6):1030-1037
2017Gordon KB, Betts KA, Sundaram M, Signorovitch JE, Li J, Xie M, Wu EQ, Okun MM
-
Inpatient Admissions and Costs Associated with Persistent Use of Dalfampridine Extended-Release in Multiple Sclerosis: A Claims Database Analysis
Journal of Managed Care and Specialty Pharmacy. Jul 2017;23(7):771-780
2017Guo A, Niyazov A, Macaulay D, Terasawa E, Schmerold L, Wu EQ, Krieger S
-
Attributes of nuclear imaging centers impacting physician referrals for single-photon emission computed tomography myocardial perfusion imaging tests
Journal of Medical Economics. Aug 2017;20(8):777-785
2017Li J, Houle CR, Spalding JR, Yang H, Xiang CQ, Kitt TM, Kristy RM, Wu EQ
-
Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant pr
Journal of Medical Economics. Feb 2017;20(2):121-128
2017Massoudi M, Balk M, Yang H, Bui CN, Pandya BJ, Guo J, Song Y, Wu EQ, Brown B, Barlev A, Flanders S
-
Real-world costs of ischemic stroke by discharge status
Current Medical Research and Opinion. Feb 2017;33(2):371-378
2017Mu F, Hurley D, Betts KA, Messali AJ, Paschoalin M, Kelley C, Wu EQ
-
Outcomes-Based Contracting Experience: Research Findings from U.S. and European Stakeholders
Journal of Managed Care & Specialty Pharmacy. 2017;23(10)
2017Nazareth T, Ko JJ, Sasane R, Frois C, Carpenter S, Demean S, Vegesna A, Wu E, Navarro RP
-
Retreatment Rates Among Endometriosis Patients Undergoing Hysterectomy or Laparoscopy
Journal of Women's Health. Jun 2017;26(6):644-654
2017 -
Systematic Literature Review of the Impact of Endocrine Monotherapy and in Combination with Targeted Therapy on Quality of Life of Postmenopausal Women with HR+/HER2- Advanced Breast Cancer.
Advances in Therapy. Dec 2017;34(12):2566-2584
2017Zhou Z, Tang DH, Xie J, Ayyagari R, Wu E, Niravath PA
-
Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive A(1)
Advances in Therapy. Jan 2017;34(1):207-220
2017Harrington R, Lee E, Yang H, Wei J, Messali A, Azie N, Wu EQ, Spalding J
-
Healthcare Resource Use, Costs, and Disease Progression Associated with Diabetic Nephropathy in Adults with Type 2 Diabetes: A Retrospective Observational Study
Diabetes Therapy. Jun 2017;8(3):555-571
2017Zhou Z, Chaudhari P, Yang H, Fang AP, Zhao J, Law EH, Wu EQ, Jiang R, Seifeldin R
-
A Risk Score for Fluconazole Failure among Patients with Candidemia
Antimicrobial Agents Chemotherapy. 2017 Apr 24;61(5). pii: e02091-16. doi: 10.1128/AAC.02091-16. Print 2017 May.
2017Yang H, Ostrosky-Zeichner L, Harrington R, Azie N, Li N, Zhao J, Koo V, Wu EQ
-
The Economic Burden of Schizophrenia in the United States in 2013
Journal of Clinical Psychiatry, June 2016;77(6):764-71
2016 -
Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis
Clinical Therapeutics, 2016 05; 38(5): 1205-1216. e-pub ahead of print 2016/04/06
2016 -
Drug-Drug Interaction Associated with Mold-Active Triazoles among Hospitalized Patients
Antimicrobial Agents and Chemotherapy, 2016 06; 60(6): 3398-3406. e-pub ahead of print 2016/03/24
2016Andes D, Azie N, Yang H, Harrington R, Kelley C, Tan RD, Wu EQ, Franks B, Kristy R, Lee E, Khandelwal N, Spalding J.
-
Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy
Advances in Therapy, 2016 May
2016Hao Y, Li N, Fang AP, Koo V, Peeples M, Kageleiry A, Wu EQ, Guerin A
-
Treatment patterns and factors associated with the use of everolimus among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study
Expert Opinion on Pharmacotherapy, 2016 04; 17(9): 1189-1196. e-pub ahead of print 2016/04/08
2016Guerin A, Hao Y, Tang D, Peeples M, Fang A, Kageleiry A, Koo V, Li N, Wu EQ.
-
Network Meta-Analysis and Cost Per Responder of Tumor Necrosis Factor-alpha and Interleukin Inhibitors in the Treatment of Active Ankylosing Spondylitis
Rheumatology and Therapy, 2016 07: 1-14
2016Betts KA, Griffith J, Song Y, Mittal M, Joshi A, Wu EQ, Ganguli A.
-
Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2- metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective cla
Journal of Medical Economics, 2016 19(4): 414-423
2016Li N, Hao Y, Koo V, Fang A, Peeples M, Kageleiry A, Wu EQ, Guerin A.
-
Effectiveness of Everolimus Versus Endocrine Monotherapy or Chemotherapy Among HR+/HER2- mBC Patients With Multiple Metastatic Sites
Clinical Therapeutics, 2016 04; 38(4): 905-917. e-pub ahead of print 2016/03/08
2016Li N, Hao Y, Xie J, Lin PL, Koo V, Ohashi E, Wu EQ
-
Time on treatment of everolimus and chemotherapy among postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative metastatic breast cancer: A retrospective c
Current Medical Research and Opinion, 2016 02; 32(2): 385-394
2016Li N, Hao Y, Kageleiry A, Peeples M, Fang A, Koo V, Wu EQ, Guerin A.
-
Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A
Journal of Blood Medicine, 2016 07; 7: 129-137. e-pub ahead of print 2016/07/23
2016Pocoski J, Li N, Ayyagari R, Church N, Maas Enriquez M, Xiang Q, Kelkar S, Du EX, Wu EQ, Xie J
-
Burden of illness among patients with fragile X syndrome (FXS): a Medicaid perspective
Current Medical Research and Opinion, Opin 2016 03; 32(3): 405-416. e-pub ahead of print 2015/11/14
2016Nazareth T, Li N, Marynchenko M, Zhou Z, Chopra P, Signorovitch J, Wu E, Ahmed S, Marvel J, Sasane R
-
Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant pr
Journal of Medical Economics, 2016 09: 1-8
2016Massoudi M, Balk M, Yang H, Bui CN, Pandya BJ, Guo J, Song Y, Wu EQ, Brown B, Barlev A, Flanders S.
-
Physician experiences and preferences in the treatment of HR+/HER2- metastatic breast cancer in the United States: a physician survey
Clinical Therapeutics, 2016 02; 5(2): 209-220
2016Lin PL, Hao Y, Xie J, Li N, Zhong Y, Zhou Z, Signorovitch JE, Wu EQ
-
Survival in patients with non-metastatic breast cancer treated with adjuvant trastuzumab in clinical practice
SpringerPlus, 2016 03; 5: 395. e-pub ahead of print 2016/04/06
2016Gallagher CM, More K, Masaquel A, Kamath T, Guerin A, Ionescu-Ittu R, Nitulescu R, Gauthier-Loiselle M, Sicignano N, Butts E, Wu EQ, Barnett B
-
Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer
Breast Cancer Research and Treatment, 2016 05; 157(1): 145-156. e-pub ahead of print 2016/04/25
2016Gallagher CM, More K, Kamath T, Masaquel A, Guerin A, Ionescu-Ittu R, Gauthier-Loiselle M, Nitulescu R, Sicignano N, Butts E, Wu EQ, Barnett B
-
Brentuximab Vedotin Compared with Other Therapies in Relapsed/Refractory Hodgkin Lymphoma Post ASCT: Median Overall Survival Meta-Analysis
Curr Med Res Opin. 2015 May 7:1-48
2015Bonthapally V, Yang H, Ayyagari R, Tan RD, Cai S, Wu E, Gautam A, Chi A, Huebner D
-
Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data
Curr Med Res Opin. 2015 May; 31(5):993-1001
2015Bonthapally V, Wu E, Macalalad A, Yang H, Shonukan O, Liu Y, Chi A, Huebner D.
-
The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas
Curr Med Res Opin. 2015 Mar; 31(3):537-45
2015Macalalad AR, McAuliffe M, Yang H, Kageleiry A, Zhong Y, Wu EQ, Shonukan O, Bonthapally V.
-
Healthcare utilization and costs in women diagnosed with endometriosis before and after diagnosis: a longitudinal analysis of claims databases
Fertil Steril. 2015 Jan; 103(1):163-71
2015 -
Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting
Cancer Med. 2015 May 20. doi: 10.1002/cam4.475. [Epub ahead of print]
2015Gibney GT, Gauthier G, Ayas C, Galebach P, Wu EQ, Abhyankar S, Reyes C, Guerin A, Yim YM
-
ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer
Cancer Epidemiol. 2015 Jun;39(3):307-12
2015Guerin A, Sasane M, Zhang J, Macalalad AR, Galebach P, Jarvis J, Kageleiry A, Culver K, Wu EQ, Wakelee H
-
Psoriasis and risk of diabetes-associated microvascular and macrovascular complications
J Am Acad Dermatol. 2015 Jun;72(6):968-977.e2
2015Armstrong AW, Guerin A, Sundaram M, Wu EQ, Faust ES, Ionescu-Ittu R, Mulani P
-
Treatment persistence in attention deficit/hyperactivity disorder: a retrospective analysis of patients initiated on lisdexamfetamine vs other medications
J Med Econ. 2013 Nov;16(11):1275-89
2015Setyawan J, Guerin A, Hodgkins P, Gauthier G, Cloutier M, Wu E, Erder MH
-
Costs and Resource Utilization Associated With Anemia and Rash in Chronic Hepatitis C Patients Treated With Direct-Acting Antiviral Agents in the United States
Clin Ther. 2015 Jun 22
2015Le TK, Macaulay D, Kalsekar A, Yuan Y, Sorg RA, Wei J, Wu EQ
-
Nomenclature and traceability debate for biosimilars: small-molecule surrogates lend support for distinguishable nonproprietary names
Adv Ther. 2015 Mar;32(3):270-83
2015Chao J, Skup M, Alexander E, Tundia N, Macaulay D, Wu E, Mulani P
-
The economic burden of gastrointestinal stromal tumor (GIST) recurrence in patients who have received adjuvant imatinib therapy
J Med Econ. 2015 Mar;18(3):241-8
2015 -
Treatment patterns, health care resource utilization, and costs in U.S. patients diagnosed with chronic hepatitis C infection who received telaprevir or boceprevir
J Manag Care Spec Pharm. 2015 Apr;21(4)
2015Le TK, Kalsekar A, Macaulay D, Yuan Y, Sorg RA, Behrer CR, Wei J, Wu EQ
-
Real-world treatment patterns of gout patients treated with colchicine or other common treatments for gout in acute care settings: a retrospective chart review study
Current Medical Research and Opinion. 2015
2015Shiozawa A, Cloutier M, Heroux J, Guerin A, Wu EQ, Jackson R
-
Budget impact analysis of liposomal amphotericin B and amphotericin B lipid complex in the treatment of invasive fungal infections in the United States
Appl Health Econ Health Policy. 2014 Feb; 12(1):85-93
2014 -
Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab-carboplatin-paclitaxel and carboplatin-paclitaxel: a retrospective cohort study
Lung Cancer. 2014 Dec;86(3):350-7
2014Langer C, Ravelo A, Hazard SJ, Guerin A, Ionescu-Ittu R, Latremouille-Viau D, Wu EQ, Ramalingam S
-
Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world setting
Oncologist. 2014 Sep;19(9):901-8
2014Hurvitz S, Guerin A, Brammer M, Guardino E, Zhou ZY, Latremouille Viau D, Wu EQ, Lalla D
-
The impact of moderate-to-severe Crohn's Disease on employees' salary growth
Inflamm Bowel Dis. 2014 Oct;20(10):1734-8
2014Loftus EV Jr, Skup M, Ozbay AB, Wu E, Guerin A, Chao J, Mulani P
-
Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia
Curr Med Res Opin. 2014 Nov;30(11):2317-28
2014Guerin A, Chen L, Ionescu-Ittu R, Marynchenko M, Nitulescu R, Hiscock R, Keir C, Wu EQ
-
Distribution and drivers of costs in type 2 diabetes mellitus treated with oral hypoglycemic agents: a retrospective claims data analysis
J Med Econ. 2014 Sep;17(9):646-57
2014Bron M, Guerin A, Latremouille-Viau D, Ionescu-Ittu R, Viswanathan P, Lopez C, Wu EQ
-
Risk of developing colorectal cancer and benign colorectal neoplasm in patients with chronic constipation
Aliment Pharmacol Ther. 2014 Jul;40(1):83-92
2014Guerin A, Mody R, Fok B, Lasch KL, Zhou Z, Wu EQ, Zhou W, Talley NJ
-
Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase
Curr Med Res Opin. 2014 Jul;30(7):1345-52
2014 -
Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia
J Med Econ. 2014 Feb;17(2):89-98
2014 -
Comparison of treatment patterns and economic outcomes in metastatic breast cancer patients initiated on trastuzumab versus lapatinib: a retrospective analysis
Springerplus. 2014 May 8;3:236
2014Guerin A, Lalla D, Gauthier G, Styles A, Wu EQ, Masaquel A, Brammer MG
-
Real-world adherence and persistence associated with nebivolol or hydrochlorothiazide as add-on treatment for hypertension
Curr Med Res Opin. 2014 Apr;30(4):637-43
2014Chen S, Macaulay D, Swallow E, Diener M, Farooqui S, Xie J, Wu EQ
-
Treatment patterns, prescribing decision drivers, and predictors of complete response following disease recurrence in gastrointestinal stromal tumor patients-a chart extract-based approach
J Gastrointest Cancer. 2014 Dec;45(4):431-40
2014Conley AP, Guerin A, Sasane M, Gauthier G, Schwiep F, Keir CH, Wu EQ
-
Impact of timely switching from imatinib to a second-generation tyrosine kinase inhibitor after 12-month complete cytogenetic response failure: a chart review analysis
Clinical Lymphoma, Myeloma & Leukemia, 2014
2014DeAngelo DJ, Chen L, Guerin A, Styles A, Giguere-Duval P, Wu EQ
-
Development and validation of a claims-based prediction model for COPD severity
Respiratory Medicine, June 2013
2013Macaulay D, Sun SX, Sorg RA, Yan SY, De G, Wu EQ, Simonelli PF
-
Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib
Curr Med Res Opin. 2013 Sep;29(9):1075-82
2013Goldberg SL, Chen L, Guerin A, Macalalad AR, Liu N, Kaminsky M, Ericson SG, Wu EQ
-
A longitudinal analysis of costs associated with change in disease activity in systemic lupus erythematosus
J Med Econ. 2013;16(6):793-800
2013Kan H, Guerin A, Kaminsky MS, Yu AP, Wu EQ, Denio A, Priti J, Narayanan S, Molta C
-
Comparison of the long-term risk of recurrence and other clinical outcomes in GIST patients receiving imatinib as adjuvant therapy--a retrospective chart extract-based approach
J Gastrointest Cancer. 2013 Jun;44(2):190-8
2013Conley AP, Guerin A, Sasane M, Gauthier G, Schwiep F, Keir CH, Wu EQ
-
Outcomes in atrial fibrillation patients on combined warfarin & antiarrhythmic therapy
Int J Cardiol. 2013 Jul 31;167(2):564-9
2013Guerin A, Lin J, Jhaveri M, Wu EQ, Yu AP, Cloutier M, Gauthier G, Alpert JS
-
Comparison of therapy augmentation and deviation rates from the recommended once-daily dosing regimen between LDX and commonly prescribed long-acting stimulants for the treatment of ADHD in youth and
J Med Econ. 2013 Oct;16(10):1203-15
2013Setyawan J, Hodgkins P, Guerin A, Gauthier G, Cloutier M, Wu E, Erder MH
-
Comparing treatment adherence of lisdexamfetamine and other medications for the treatment of attention deficit/hyperactivity disorder: a retrospective analysis
J Med Econ. 2013 Jul;16(7):962-75
2013Setyawan J, Hodgkins P, Guerin A, Gauthier G, Cloutier M, Wu EQ, Erder MH
-
-
Comparing nilotinib with dasatinib as second-line therapies in patients with chronic myelogenous leukemia resistant or intolerant to imatinib – a retrospective chart review analysis
Current Medical Research and Opinion, 2013
2013Griffin JD, Guerin A, Chen L, Macalalad AR, Luo J, Ionescu-Ittu R, Wu EQ
-
Risks of developing psychiatric disorders in pediatric patients with psoriasis
J Am Acad Dermatol. 2012 Jan 11.
2012Kimball A, Wu EQ, Guérin A, Yu AP, Tsaneva M, Gupta S, Bao Y, Mulani P
-
Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution
Pediatr Pulmonol. 2012 Jan;47(1):44-52. doi: 10.1002/ppul.21521. Epub 2011 Aug 3.
2012Sawicki G, Signorovitch J, Zhang J, Latremouille-Viau D, von Wartburg M, Wu EQ, Shi L
-
Hypoglycaemia and accident risk in people with type 2 diabetes mellitus treated with non-insulin antidiabetes drugs
Diabetes, Obesity and Metabolism, November 2012
2012Signorovitch J, Macaulay D, Diener M, Yan Y, Wu EQ, Gruenberger J, Frier B
-
Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of ADHD
Pharmacoeconomics. 2012 Aug 1;30(8):e1-15
2012Sikirica V, Haim Erder M, Xie J, Macaulay D, Diener M, Hodgkins P, Wu EQ
-
Identifying patient subgroups who benefit most from a treatment: using administrative claims data to uncover treatment heterogeneity
J Med Econ. 2012; 15(6):1078-87
2012Erder MH, Signorovitch JE, Setyawan J, Yang H, Parikh K, Betts KA, Xie J, Hodgkins P, Wu EQ
-
Treatment patterns and economic burden of metastatic and recurrent locally-advanced head and neck cancer patients
J Med Econ. 2012; 15(4):786-95
2012Kim Le T, Winfree KB, Yang H, Marynchenko M, Yu AP, Frois C, Wu EQ.
-
A pulmonary exacerbation risk score among cystic fibrosis patients not receiving recommended care
Pediatr Pulmonol. 2013 Oct;48(10):954-61
2012Sawicki GS, Ayyagari R, Zhang J, Signorovitch JE, Fan L, Swallow E, Latremouille-Viau D, Wu EQ, Shi L
-
Comorbidity burden, healthcare resource utilization, and costs in chronic gout patients refractory to conventional urate-lowering therapy
2012 Nov;19(6):e157-66
2012Wu EQ, Forsythe A, Guerin A, Yu AP, Latremouille-Viau D, Tsaneva M
-
Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative advanced breast cancer
Journal of Medical Economics, 1-26, November 16, 2012
2012 -
Economic burden of dermatologic adverse drug reactions in the treatment of colorectal, non-small cell lung, and head and neck cancers
Journal of Medical Economics, 1-30, November 27, 2012
2012Ray S, Bonthapally V, Holen K, Gauthier G, Wu EQ, Cloutier M, Guérin A
-
Re: Stopeck A, Rader M, Henry D, et al. Cost-effectiveness of denosumab vs. zoledronic acid for prevention of skeletal-related events
Journal of Medical Economics; December 5, 2012 [Letter to the Editor]
2012Xie J, Diener M, Sorg R, Wu EQ, Namjoshi M
-
Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs
Postgrad Med. 2012 Jan; 124(1):124-32
2012 -
Comparative effectiveness research using matching-adjusted indirect comparison: an application to treatment with guanfacine extended release or atomoxetine in children with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder
Pharmacoepidemiology and Drug Safety, 2012
2012Signorovitch J, Erder MH, Xie J, Sikirica V, Lu M, Hodgkins PS, Wu EQ
-
Monitoring and switching patterns of patients with chronic myeloid leukemia treated with imatinib in community settings: a chart review analysis
Current Medical Research and Opinion, 2012
2012Chen L, Guérin A, Xie J, Wu EQ, Yu AP, Ericson SG, Jabbour E
-
Risk-benefit analysis of adalimumab versus traditional non-biologic therapies for patients with Crohn's disease
Inflammatory Bowel Diseases. 2011, 17(1), 127-140
2011Loftus E Jr, Johnson S, Wang S, Wu EQ, Mulani PM, Chao J
-
Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities
Am J Clin Dermatol. 2011 Feb 1;12(1):51-62
2011Kimball A, Bensimon A, Guerin A, Yu AP, Wu EQ, Okun M, Bao Y, Gupta S, Mulani P
-
Economic burden of comorbidities in patients with psoriasis is substantial
J Eur Acad Dermatol Venereol. 2011 Feb; 25(2):157-63. Epub 2010 Jun 17.
2011Kimball A, Guerin A, Tsaneva M, Yu AP, Wu EQ, Gupta S, Bao Y, Mulani P
-
Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes: a matching-adjusted indirect comparison of randomized trials
Clin Drug Investig. 2011;31(9):665-74. doi: 10.2165/11592490-000000000-00000.
2011Signorovitch J, Wu EQ, Swallow E, Kantor E, Fan L, Gruenberger J
-
Achieving glycemic goal with initial versus sequential combination therapy using metformin and pioglitazone in type 2 diabetes mellitus
Curr Med Res Opin. 2011 Jan; 27(1):189-95. Epub 9 Dec, 2010
2011Pandya B, Bron M, McCall T, Yu AP, Chen K, Mattson M, Wu EQ
-
Economic Outcomes of Switching Treatment in Major Depressive Disorder Patients
Am J Pharm Benefi ts. 2011;3(6):e111-e120
2011Marynchenko M, Yu AP, Lauzon V, Ramakrishnan K, Wu EQ, Ben-Hamadi R, Blum S, Erder M, Bose A
-
Remission of major depressive disorder without adverse events: a comparison of escitalopram versus serotonin norepinephrine reuptake inhibitors
Curr Med Res Opin. 2011 Jun;27(6):1089-96. Epub 2011 Mar 28. Erratum in: Curr Med Res Opin. 2011 Sep;27(9):1708.
2011Signorovitch J, Ramakrishnan K, Ben-Hamadi R, Yu AP, Wu EQ, Dworak H, Erder M
-
Economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor
Ann Pharmacother. 2011 Mar 17.
2011Wu EQ, Yu AP, Lauzon V, Ramakrishnan K, Marynchenko M, Ben-Hamadi R, Blum S, Erder M
-
Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials
Curr Med Res Opin. 2011 Jun;27(6):1263-71. Epub 2011 Apr 28
2011Signorovitch J, Wu EQ, Betts K, Parikh K, Kantor E, Guo A, Bollu V, Williams D, Wei L, DeAngelo D
-
The benefits of timely intervention with zoledronic acid in patients with metastatic prostate cancer to bones: a retrospective study of US Veterans
Prostate Cancer Prostatic Dis. 2011 Mar;14(1):79-84. Epub 2010 Dec 21
2011Velde N, Wu EQ, Guo A, Lu M, Yu AP, Sharma H, Liu J, Fan C, Shi L
-
Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases
Journal of Managed Care Pharmacy. 2011;17(8):621-34
2011Xie J, Namjoshi M, Wu EQ, Parikh K, Diener M, Yu AP, Guo A, Culver KW
-
Comparison of skeletal complications and treatment patterns associated with early vs. delayed zoledronic acid therapy in multiple myeloma
Clin Lymphoma Myeloma Leuk. 2011 Aug;11(4):326-35. Epub 2011 May 6
2011Wu EQ, Bensimon A, Marynchenko M, Namjoshi M, Guo A, Yu AP, Ericson S, Raje N
-
Increased risks of developing anxiety and depression in young patients with Crohn's disease
Am J Gastroenterol. 2011 Sep;106(9):1670-7. doi: 10.1038/ajg.2011.142. Epub 2011 May 3.
2011Loftus E Jr, Guerin A, Yu AP, Wu EQ, Yang M, Chao J, Mulani P
-
Clinical and economic outcomes of multiple versus single long-acting inhalers in COPD
Respir Med. 2011 Dec;105(12):1861-71. Epub 2011 Jul 31.
2011Yu AP, Guerin A, de Leon DP, Ramakrishnan K, Wu EQ, Mocarski M, Blum S, Setyawan J
-
Cost-effectiveness analysis of roflumilast/tiotropium therapy versus tiotropium monotherapy for treating severe-to-very severe COPD
J Med Econ. 2011;14(6):805-15. Epub 2011 Oct 12.
2011Sun S, Marynchenko M, Banerjee R, Cheng D, Mocarski M, Yin D, Yu AP, Wu EQ
-
Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers
J Med Econ. 2011;14(4):486-96. Epub 2011 Jun 16.
2011Yu AP, Guerin A, Ponce de Leon D, Ramakrishnan K, Wu EQ, Mocarski M, Blum S, Setyawan J
-
Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer
J Med Econ. 2011; 14(5):542-52
2011 -
Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis
J Med Econ. 2011; 14(3):315-23
2011 -
Copayment level, treatment persistence, and health care utilization in hypertension patients treated with single-pill combination therapy
J Med Econ. 2011 Mar 30.
2011Yang W, Kahler KH, Fellers T, Orloff J, Chang J, Bensimon AG, Wu EQ, Fan CP, Yu AP
-
Compliance, persistence, healthcare resource use, and treatment costs associated with aliskiren plus ARB versus ACE inhibitor plus ARB combination therapy
Am J Cardiovasc Drugs. 2011;11(1):21-32
2011Chang J, Yang W, Kahler KH, Fellers T, Orloff J, Bensimon AG, Yu AP, Fan CP, Wu EQ
-
Impact of initiation timing of SSRI or SNRI on depressed adolescent health care utilization and costs
J Med Econ. 2011;14(4):508-15. Epub 2011 Jun 21
2011Ben-Hamadi R, Bergman R, Kaltenboeck A, Wu EQ, Xie J, Yu AP, Blum S, Erder M
-
Healthcare utilization and costs incurred by patients with major depression after being switched from escitalopram to another SSRI for non-medical reasons
J Med Econ. 2010;13(2):314-323
2010Wu E, Ben-Hamadi R, Yu A, Tang J, Haim Erder M, Bose A
-
Impact of adalimumab on symptoms of psoriatic arthritis in patients with moderate to severe psoriasis: a pooled analysis of randomized clinical trials
Dermatology. 2010;220(1):1-7. Epub 2009 Nov 19
2010Mease P, Signorovitch J, Yu A, Wu E, Gupta S, Bao Y, Mulani P
-
The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial
J Am Acad Dermatol. 2010 May;62(5):812-8. Epub 2010 Mar 9
2010Menter A, Augustin M, Signorovitch J, Yu A, Wu E, Gupta S, Bao Y, Mulani P
-
High prevalence of potential drug-drug interactions for psoriasis patients prescribed methotrexate or cyclosporine for psoriasis
Dermatology. 2010;220(2):128-37. Epub 2010 Feb 3
2010Saurat J, Guerin A, Yu A, Latremouille-Viau D, Wu E, Gupta S, Bao Y, Mulani P
-
Direct costs associated with initiating NPH insulin versus glargine in patients with type 2 diabetes: a retrospective database analysis
Diabetes Res Clin Pract. 2010 Jan;87(1):108-16
2010Lee L, Yu A, Johnson S, Birnbaum H, Atanasov P, Buesching D, Jackson J, Davidson J
-
Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients
Current Medical Research and Opinion. 2010 Jan;26(1):61-9
2010Wu E, Johnson S, Beaulieu N, Arana M, Bollu V, Guo A, Coombs J, Feng W, Cortes J
-
Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment
Pharmacoeconomics. 2010 Oct 1;28(10):935-45. doi: 10.2165/11538370-000000000-00000
2010Signorovitch J, Wu E, Yu A, Gerrits C, Kantor E, Bao Y, Gupta S, Mulani P
-
Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihypertensives
Curr Med Res Opin. 2010 Sep;26(9):2065-76
2010Yang W, Chang J, Kahler K, Fellers T, Orloff J, Wu E, Bensimon A
-
Chart review of patients on valsartan-based single-pill combinations vs. ARB-based free combinations for BP goal achievement
Curr Med Res Opin. 2010 Sep;26(9):2203-12
2010Chang J, Yang W, Fellers T, Kahler K, Orloff J, Xie J, Tsaneva M, Yu A, Wu EQ
-
Benefit-risk analysis of adalimumab vs methotrexate and placebo in the treatment of moderate to severe psoriasis
J Am Acad Dermatol. 2010 Oct 6. [Epub ahead of print]
2010Reich K, Signorovitch J, Ramakrishnan K, Yu A, Wu EQ, Gupta S, Bao Y, Mulani P
-
Economic impact of switching from valsartan to other angiotensin receptor blockers in patients with hypertension
Curr Med Res Opin. 2010 Apr; 26(4):849-60
2010Signorovitch J, Zhang J, Wu EQ, Latremouille-Viau D, Yu AP, Dastani HB, Kahler KH
-
Systematic review: the costs of ulcerative colitis in Western countries
Aliment Pharmacol Ther. 2010 Apr;31(7):693-707
2010Cohen R, Yu AP, Wu EQ, Xie J, Mulani P, Chao J
-
Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia
Current Medical and Research Opinion, December 2010, Vol. 26, No. 12 , Pages 2861-2869
2010 -
Economic consequence of switching to citalopram after its generic entry for adult patients with major depressive disorder (MDD) treated with escitalopram
Journal of Medical Economics, 2010
2010Yu A, Xie J, Bensimon A, Parikh K, Wu E, Ben-Hamadi R, Blum S, Haim Erder
-
The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients w Crohn's
Aliment Pharmacol Ther. 2010 Nov; 32(10):1228-39
2010Lichtiger S, Binion D, Wolf D, Present D, BensimonA, Wu EQ, Yu AP, Cardoso A, Chao J, Mulani P, Lomax K, Kent J
-
Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn's disease
Pharmacoeconomics. 2009;27(7):609-21
2009Yu AP, Johnson S, Wang ST, Atanasov P, Tang J, Wu E, Chao J, Mulani PM
-
Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial
Am J Gastroenterol. 2009 May;104(5):1170-9
2009Colombel JF, Sandborn WJ, Rutgeerts P, Kamm MA, Yu AP, Wu EQ, Pollack PF, Lomax KG, Chao J, Mulani PM
-
Economic burden of psoriasis compared to the general population and stratified by disease severity
Curr Med Res Opin. 2009 Oct;25(10):2429-38
2009Yu AP, Tang J, Xie J, Wu EQ, Gupta SR, Bao Y, Mulani PM
-
Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone-budesonide and formoterol-salmeterol
Clin Ther. 2009 Dec;31(12):2779-803
2009Frois C, Wu E, Ray S, Colice G
-
Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease
Eur J Gastroenterol Hepatol. 2009 Nov;21(11):1302-9
2009Loftus E Jr, Johnson S, Yu A, Wu E, Chao J, Mulani P
-
Treatment persistence, healthcare utilization and costs in adult patients with major depressive disorder: a comparison between escitalopram
J Med Econ. 2009 Jun;12(2):124-35. doi: 10.3111/13696990903093537.
2009Wu EQ, Greenberg PE, Yang E, Yu AP, Ben-Hamadi R, Erder MH.
-
Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis.
Curr Med Res Opin 2008 Aug;24(8):2229-40.
2008Wu E, Chen L, Birnbaum H, Yang E, Cifaldi M
-
Loss of Treatment Response to Infliximab Maintenance Therapy in Crohn's Disease: A Payor Perspective
Value Health, May 16, 2008
2008Wu E, Mulani P, Yu A, Tang J, Pollack PF
-
Comparison of escitalopram versus citalopram for the treatment of major depressive disorder in a geriatric population
Current Medical Research and Opinion 2008;24(9):2587-2595
2008Wu E, Greenberg P, Yang E, Yu A, Erder M
-
Disease-related and all-cause health care costs of elderly patients with gout
J Manag Care Pharm 2008 Mar;14(2):164-75
2008Wu E, Patel P, Yu A, Mody R, Cahill K, Tang J, Krishnan E
-
Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study
Gastroenterology. 2008 Aug 3.
2008Feagan B, Panaccione R, Sandborn W, D'Haens G, Schreiber S, Rutgeerts P, Loftus EV J, Lomax K, Yu AP, Wu EQ
Chao J, Mulani P -
Comparison of treatment persistence, hospital utilization, costs among major depressive disorder geriatric patients treated with escitalopram
Current Medical Research and Opinion 2008;24(10):2805-13
2008Wu E, Greenberg P, Yang E, Yu A, Ben-Hamadi R, Erder M
-
Mapping FACT-P and EORTC QLQ-C30 to the EQ-5D Health Utility in Metastatic Hormone-Refractory Prostate Cancer Patients
Value Health; Sep-Oct;10(5):408-14
2007Wu E, Mulani P, Farrell, Sleep D
-
Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents
Current Medical Research and Opinion; Sep;23(9):2157-69
2007Yu A, Wu E, Birnbaum H, Emani S, Fay M, Pohl G, Wintle M, Yang E, Oglesby A
-
Use of Inhaled Corticosteroids and Healthcare Costs in Mild Persistent Asthma
Journal of ASTHMA; Jul-Aug;44(6):479-83
2007Colice G, Wu E, Birnbaum H, Daher M, Marynchenko M
-
Retrospective Economic and Outcomes Analysis Using International Databases: A Review
PharmacoEconomics; 25(7):563-76
2007Shi L, Wu E, Hodges M, Yu A, Birnbaum H
-
Estimated prevalence of peripheral neuropathy and associated pain in adults with diabetes in France
Current Medical Research and Opinion; Sep;23(9):2035-42
2007Wu E, Borton J, Said G, T.K. Le, Monz B, Rosilio M, Avoinet S
-
Impact of cardiometabolic risk factor clusters on health-related quality of life in the US
Obesity; Feb;15(2):511-21
2007Sullivan P, Ghushchyan V, Wyatt H, Wu E, Hill J
-
Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data
Curr Med Res Opin 2007 Aug;23(8):1749-59
2007Wu E, Chen L, Birnbaum H, Yang E, Cifaldi M
-
Mapping FACT-P and EORTC QLQ-C30 to patient health status measured by EQ-5D in metastatic hormone-refractory prostate cancer patients
Cancer 2007 Mar;109(6):1090-6
2007Wu E, Mulani P, Farrell M, Sleep D
-
Productivity costs associated with cardiometabolic risk factor clusters in the United States
Value Health 2007 Nov-Dec;10(6):443-50
2007Sullivan P, Ghushchyan V, Wyatt H, Wu E, Hill J
-
Retrospective economic and outcomes analyses using non-US databases: a review
Pharmacoeconomics 2007;25(7):563-76
2007Shi L, Wu E, Hodges M, Yu A, Birnbaum H
-
HPV prevalence, E6 sequence variation and physical state of HPV16 isolates from patients with cervical cancer in Sichuan, China
Gynecologic Oncology; 2007 Jan;104(1):77-85. Epub 2006 Sep 12.
2007Qiu A, Wu E, Yu X, Jiang C, Jin Y, Wu Y, Chen Y, Chen Y, Shan Y, Zhang G, Fan Y, Zha X, Kong W
-
Impact of Single-Photon Emission Computed Tomography (SPECT) Use After Acute Myocardial Infarction (AMI) on Cardiac Procedure Rates and Hospital Length of Stay
J Nucl Cardiol 2007;14(4):S115
2007Wu E, Persson B, Beaulieu N, White L, Spalding J, Mahmarian J
-
Annual prevalence of diagnosed schizophrenia in the USA: a claims data analysis approach
Psychol Med. 2006 Nov;36(11):1535-40. Epub 2006 Aug 15.
2006Wu EQ, Shi L, Birnbaum H, Hudson T, Kessler R
-
Development of a COPD Severity Score
Curr Med Res Opin 2006;22(9):1679-87
2006Wu E, Birnbaum H, Cifaldi M, Kang Y, Mallet D, Colice G
-
Cost-Effectiveness of Duloxetine versus Routine Treatment for U.S. Patients With Diabetic Peripheral Neuropathic Pain
J Pain 2006 Jun;7(6):399-407
2006Wu E, Birnbaum H, Mareva M, Kim Le T, Robinson R, Rosen A, Gelwicks S
-
Lifetime Costs of Patients with Clinically-Detected Uterine Fibroids: An Employer's Perspective
Drug Benefit Trends, 2006, 18(7): 405-10
2006Wu E, Ben-Hamadi R, Birnbaum H, Farrell M, Spalding J, Stang P, Hartmann K
-
Impact of stroke on health-related quality of life in the noninstitutionalized population in the United States
Stroke, 2006 Oct;37(10):2567-72
2006Xie J, Wu E, Zheng Z, Croft J, Greenlund K, Mensah G, Labarthe D
-
Annual costs associated with diagnosis of uterine leiomyomata
Obstet Gynecol 2006 Oct;108(4):930-7
2006Hartmann K, Birnbaum H, Ben-Hamadi R, Wu E, Farrell M, Spalding J, Stang P
-
Health Care and Work Loss Costs Associated with Persistent Asthma Patients in a Privately Insured Population
Journal of Occupational and Environmental Medicine, 2006 Aug;48(8):794-802
2006Colice G, Wu E, Birnbaum H, Daher M, Marynchenko M, Faruqi R, Varghese S
-
Healthcare and workloss costs associated with patients with persistent asthma in a privately insured population
J Occup Environ Med 2006 Aug;48(8):794-802
2006Colice G, Wu E, Birnbaum H, Daher M, Marynchenko M, Varghese S
-
A Retrospective Claims Database Analysis to Assess Patterns of Interstitial Cystitis (IC) Diagnosis
Curr Med Res Opin 2006 March;22(3):495-500
2006Wu E, Birnbaum H, Kang Y, Parece A, Mallett D, Taitel H, Evans R
-
Interstitial Cystitis: Cost, Treatment and Co-morbidities in an Employed Population
Pharmacoeconomics 2006;24(1):55-65
2006Wu E, Birnbaum H, Mareva M, Parece A, Huang Z, Mallett D, Taitel H
-
The Economic Burden of Schizophrenia in the United States in 2002
J Clin Psychiatry 2005. Sep;66(9):1122-9
2005Wu E, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M, Aggarwal J.
-
Employees With Overactive Bladder: Work Loss Burden
J Occup Environ Med. 2005 May;47(5):439-46.
2005Wu EQ, Birnbaum H, Marynchenko M, Mareva M, Williamson T, Mallett D
-
Economic burden and co-morbidities of atrial fibrillation in a privately insured population
Curr Med Res Opin. 2005 Oct;21(10):1693-9.
2005Wu EQ, Birnbaum HG, Mareva M, Tuttle E, Castor AR, Jackman W, Ruskin J.
-
The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R)
Biol Psychiatry. 2005 Oct 15;58(8):668-76. Epub 2005 Jul 14
2005Kessler RC, Birnbaum H, Demler O, Falloon IR, Gagnon E, Guyer M, Howes MJ, Kendler KS, Shi L, Walters E, Wu EQ
-
China’s urban health insurance reform experiment in Zhenjiang: cost and utilization analyses
The Economics of Health Care in Asia-Pacific Countries, Edward Elgar Publishing Limited
2002Liu G, Cai R, Chao S, Xiong X, Zhao Z, Wu E
Events
-
May 15, 2022
-
November 6, 2022
-
November 12, 2023
News
-
April 11, 2024
-
February 26, 2024
-
February 1, 2024
-
December 7, 2023
-
December 6, 2023
-
October 23, 2023
-
February 13, 2023
-
November 1, 2022
-
May 12, 2022
-
March 1, 2022
-
February 11, 2022
-
July 20, 2021
-
April 13, 2021
-
February 9, 2021
-
January 12, 2021
-
Health Care Bulletin
Fulfilling the Promise: Real-World Data and Real-World Evidence in Action
-
Health Care Bulletin
Progress on HTA and Pharmacoeconomics in Asia
-
Health Care Bulletin
Bringing Precision Medicine to Market
-
Health Care Bulletin
Recalibrating Predictions of Long-Term Survival Benefits for Novel Cancer Therapies
-
Video
Eric Wu and Min Yang - Patient Reported Outcomes
-
Health Care Bulletin
Biopharma Value-Based Pricing: How to Make It Work?
